Oxaliplatin

Drug Profile

Oxaliplatin

Alternative Names: 1 OHP; 1670 RB; Dacotin; Dacplat; Eloxatin; Elplat; GSOX; L OHP; NSC 266046; Oxalatoplatin; Oxalatoplatinum; PR 54780; RP 54780; SR 96669

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Nagoya University
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; Debiopharm; Dr Reddys Laboratories; Pfizer; Sanofi; University of Texas M. D. Anderson Cancer Center; Yakult Honsha
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer
  • Registered Gastric cancer; Hepatocellular carcinoma; Pancreatic cancer
  • Phase II Oesophageal cancer; Ovarian cancer; Uterine cancer
  • Discontinued Acute myeloid leukaemia; Breast cancer; Diffuse large B cell lymphoma; Myelodysplastic syndromes; Nasopharyngeal cancer; Non-small cell lung cancer

Most Recent Events

  • 19 Jul 2016 Yakult initiates enrolment in a phase II trial for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan (UMIN000022450)
  • 04 Mar 2016 Debiopharm has patent protection for oxaliplatin in Japan
  • 01 Jan 2016 The University of Texas M. D. Anderson Cancer Center and Sanofi complete a phase II trial in Gastric cancer (Combination therapy) in USA (NCT00525785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top